WTA
JANX icon

Washington Trust Advisors’s Janux Therapeutics JANX Stock Holding History

Washington Trust Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-78
Closed -$1.91K – 641
2025
Q3 		$1.91K Hold
78
– – ﹤0.01% 665
2025
Q2 		$1.8K Hold
78
– – ﹤0.01% 616
2025
Q1 		$2.11K Buy
78
+49
+169% +$1.85K ﹤0.01% 611
2024
Q4 		$1.55K Buy
+29
New +$1.53K ﹤0.01% 626

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Washington Trust Advisors's JANX Position: Q4 2025 in Review

Washington Trust Advisors sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 78 shares — an estimated $1.91K sold.

Washington Trust Advisors first reported a position in JANX in Q4 2024 and held it in 4 quarters. The position peaked at $2.11K in Q1 2025. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • Washington Trust Advisors reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Washington Trust Advisors sold 78 Janux Therapeutics shares in Q4 2025, an estimated $1.91K.
  • Washington Trust Advisors first reported a position in Janux Therapeutics in Q4 2024 and held it in 4 quarters.
  • Washington Trust Advisors's Janux Therapeutics position peaked at $2.11K in Q1 2025.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Washington Trust Advisors's 13F filing for Q4 2025, filed 3 Feb 2026.